Ingredion's takeover bid for Tate & Lyle

Overview

Updated Jun 8

Ingredion and Tate & Lyle agreed the terms of a recommended all-cash deal on June 8, three days before the UK Takeover Code's June 11 deadline. Tate & Lyle's board unanimously backed the 595p-per-share offer.

Tate & Lyle published annual results on May 21 showing statutory revenue up 16% to £2.0 billion, the first full year with CP Kelco included, though like-for-like sales fell 3%. J.M. Huber's equity arm, which holds 16.8% of Tate & Lyle shares after selling CP Kelco to the company in 2024, gave an irrevocable commitment to vote in favour. Completion is targeted for the second half of 2027, pending shareholder approval and antitrust clearances in the US, EU, and UK.

Why it matters

The deal removes another big company from London's stock market and concentrates global food ingredient supply further.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

£2.74B

Agreed deal value

All-cash offer for Tate & Lyle's share capital, agreed and unanimously recommended by both boards on June 8, 2026.

59%

Premium over prior close

Premium to Tate & Lyle's 374.80p closing price on May 13, 2026, the last trading day before talks were publicly disclosed.

615p

Maximum per-share consideration

595p cash plus up to 20p in permitted dividends: 13p final dividend for the year to March 2026, plus 7p interim for the six months to September 2026.

$130M

Annual synergies targeted

Net cost synergies Ingredion expects to achieve by end of 2030, at a one-time implementation cost of $175 million.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

Nick Hampton

Chief Executive, Tate & Lyle PLC

Unanimously recommended Ingredion's 595p all-cash offer to shareholders on June 8, 2026

James P. Zallie

Chief Executive, Ingredion Inc.

Organizations Involved

Tate & Lyle PLC

Public company (LSE: TATE)

Agreed acquisition target; board unanimously recommends Ingredion's 595p all-cash offer; deal expected to close H2 2027

British food and beverage ingredients company specialising in sweeteners, texturants and dietary fibres.

Ingredion Inc.

Public company (NYSE: INGR)

Agreed all-cash acquisition of Tate & Lyle at 595p per share; deal expected to close H2 2027 subject to regulatory and shareholder approvals; combined group to generate roughly $9.9B in revenue

Chicago-based maker of food and industrial ingredients derived from corn, tapioca, potato and other plant sources.

Timeline

October 2010 May 2026

10 events Latest: May 21st, 2026 · 4 months ago

Tap a bar to jump to that date

May 2026
Tate & Lyle full-year results: statutory revenue up 16%, like-for-like down 3%
Latest Earnings

Tate & Lyle reported statutory revenue of £2.0 billion for the year ended March 31, 2026 (the first full year with CP Kelco included), up 16% year-on-year, though like-for-like revenue fell 3% against soft market demand. Adjusted EPS was 40.4p; the dividend was held flat at 19.8p. Nick Hampton said CP Kelco integration was complete.
May 21st, 2026 • 7:00 AM
Ingredion's £2.74B proposal becomes public
M&A Proposal

Ingredion proposes acquiring Tate & Lyle at 595 pence per share in cash, valuing the company at about £2.74 billion. Tate & Lyle confirms it is in discussions with advisers. The 28-day Put Up or Shut Up clock starts under the UK Takeover Code.
May 14th, 2026
Deutsche Bank raises Tate & Lyle target to 595p; shares surge 44%
Market Reaction

Deutsche Bank analyst Damian McNeela raised his target on Tate & Lyle from 460p to 595p, keeping a Buy rating, and said the bank had long argued the stock was mis-priced. Goodbody's Patrick Higgins called the combination strategically logical but flagged antitrust risk in the U.S., where the two companies overlap most. Tate & Lyle shares closed up roughly 44%; Ingredion fell about 2.8%.
May 14th, 2026
Ingredion cuts full-year guidance after Argo thermal event
Earnings

Ingredion reported Q1 2026 adjusted EPS of $2.34, down from $2.97 a year earlier, after a thermal event at its Argo, Illinois facility caused $40 million in unexpected costs — well above the $10–15 million initially estimated. The company cut full-year adjusted EPS guidance to $10.45–$11.15 from a prior midpoint of about $11.40, nine days before making the Tate & Lyle approach public.
May 5th, 2026
November 2024
CP Kelco acquisition completes
M&A

Tate & Lyle closes the CP Kelco deal, becoming a pure-play specialty food ingredients group with combined revenue above $3.4 billion.
November 12th, 2024
June 2024
Tate & Lyle agrees CP Kelco deal
M&A

Tate & Lyle agrees to buy specialty texturants and biopolymer maker CP Kelco from J.M. Huber for $1.8 billion. The acquisition is its largest in years and its central bet on specialty ingredients.
June 19th, 2024
April 2022
Tate & Lyle completes Primient joint venture
Corporate Action

Tate & Lyle sells a controlling stake in its U.S. corn-syrup and bulk-sweeteners business into a joint venture with KPS Capital Partners, branded Primient, for $1.7 billion. The deal completes its exit from commodity sweeteners.
April 1st, 2022
April 2018
Nick Hampton becomes Tate & Lyle CEO
Leadership

Hampton takes over from Javed Ahmed after three years as Chief Financial Officer. He signals plans to accelerate the company's shift toward specialty food ingredients.
April 1st, 2018
January 2018
James Zallie takes over at Ingredion
Leadership

Zallie becomes CEO of Ingredion after running its specialty ingredients arm. He pushes the company harder toward higher-margin specialty products and away from commodity sweeteners.
January 2nd, 2018
October 2010
Tate & Lyle exits European sugar refining
Corporate Action

Tate & Lyle completes sale of its European sugar refining operations, including the Thames Refinery, to American Sugar Refining for £211 million. It is the company's first major step away from its founding commodity business.
October 1st, 2010

Scenarios

Ingredion files firm offer before PUSU deadline

Likely Resolves by Jun 11, 2026

Discussed by: Tate & Lyle board statement; standard UK Takeover Code base case

Tate & Lyle's board is already in talks with advisers. The 64% premium signals Ingredion is willing to negotiate, and most public possible-offer announcements at this stage progress to a firm Rule 2.7 offer. A modest price bump to win a board recommendation is the most likely path through the June 11 deadline.

Ingredion walks away at PUSU deadline

Unlikely Resolves by Jun 11, 2026

Discussed by: Standard UK Takeover Code exit route

If Tate & Lyle's board demands a price Ingredion considers too high, or due diligence surfaces problems, Ingredion can withdraw before June 11. The Code would then bar a new approach for six months. This outcome is unusual after a public 64% premium has been put on the table, but it is the clean exit if talks break down.

Counter-bidder emerges before deal closes

Unlikely Resolves by End of 2026

Discussed by: Sector consolidation watchers

A few large agribusiness and chemicals groups, including Archer-Daniels-Midland, Cargill and BASF, could in theory match or outbid Ingredion. Antitrust concerns make a strategic counter-bid difficult, particularly for ADM. A private equity interloper is possible but would need to justify a premium above 615p without the cost synergies a strategic acquirer can claim.

Acquisition completes, Tate & Lyle delisted

Possible Resolves by Q2 2027

Discussed by: Standard cross-border M&A timetable

A firm offer at this size triggers shareholder votes plus UK Competition and Markets Authority review and likely also U.S. and EU antitrust scrutiny. Deals of this scale routinely take 9 to 15 months to close after a firm offer. Completion before mid-2027 requires a clean regulatory path and no major rival emerging.

Regulatory objection delays or blocks the deal

Possible Resolves by End of 2027

Discussed by: Goodbody analyst Patrick Higgins (flagged US overlap risk at announcement); deal conditions require US, EU, and UK antitrust clearances

The US is the most exposed jurisdiction: Ingredion and Tate & Lyle overlap in specialty starches, texturants, and sugar-reduction systems sold to the same major food manufacturers. A Federal Trade Commission challenge or forced divestitures could push completion past H2 2027. A full block is less likely given neither company dominates any single product category, but targeted remedies are possible.

Tate & Lyle shareholders vote down the scheme

Unlikely Resolves by End of 2027

Discussed by: Standard UK scheme risk; deal requires 75% in value at court-sanctioned meeting

The scheme needs approval from shareholders representing at least 75% in value at a UK court meeting — a higher bar than a simple majority. Huber Equity's 16.8% irrevocable commitment gives Ingredion a large bloc going in. But institutional holders or activists controlling more than 25% of the remaining float could still defeat the scheme if they hold out for a higher price.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 2009 – February 2010

Kraft-Cadbury takeover (2010)

Kraft Foods launched a £10.2 billion hostile bid for Cadbury in September 2009. After raising the offer to £11.5 billion and winning over Cadbury's largest shareholders, the deal closed in February 2010. Kraft then closed a Cadbury factory in Somerdale it had pledged to keep open, triggering political backlash.

Then

Cadbury was delisted from London and folded into Kraft's confectionery business. Kraft later spun the unit out as Mondelez International in 2012.

Now

The UK Takeover Panel tightened the Code in 2011, introducing the 28-day Put Up or Shut Up deadline and requiring bidders to disclose financing details. Those rules now apply to Ingredion.

Why this matters now

Sets the rulebook Ingredion is operating under. Also a reminder that US bids for British food companies can complete despite political resistance, particularly when the premium is large.

April – May 2014

Pfizer's bid for AstraZeneca (2014)

U.S. drugmaker Pfizer made a £69 billion approach for AstraZeneca in April 2014, partly driven by tax inversion. AstraZeneca's board rejected the offer as undervaluing the company. Pfizer walked away in late May after UK political opposition and shareholder pushback.

Then

AstraZeneca remained independent. Its shares fell back below Pfizer's offer level in the months after the bid lapsed.

Now

AstraZeneca's standalone strategy paid off. Its market value by 2024 far exceeded Pfizer's 2014 offer. The U.S. Treasury later tightened tax inversion rules.

Why this matters now

Shows that a determined target board can defeat even a generous US bid, particularly when the deal becomes politically sensitive. Tate & Lyle does not have AstraZeneca's UK political profile, but its board has the same option to demand more.

February 2017

Kraft Heinz's approach for Unilever (2017)

Kraft Heinz, backed by 3G Capital and Berkshire Hathaway, made a $143 billion approach for Unilever in February 2017. Unilever's board rejected it as inadequate within 48 hours. Kraft Heinz withdrew the offer two days later.

Then

Unilever launched a strategic review, accelerated cost cuts and bought back £5 billion of shares. It later sold its margarine business to KKR.

Now

Unilever stayed independent and unified its corporate structure into a single UK-listed entity in 2020. Kraft Heinz wrote down $15 billion of brand value in 2019.

Why this matters now

Shows how fast a public approach can collapse if the target board moves decisively. Also shows that resisting a takeover can pay off for shareholders long-term.